Stocks›Healthcare›MYGN

MYGN

Myriad Genetics, Inc.

NasdaqResearch view

Myriad Genetics, Inc. operates in the In Vitro & In Vivo Diagnostic Substances industry.

$4.280.00%

Oct 7 close · 1D EOD · Databento

HealthcareIn Vitro & In Vivo Diagnostic SubstancesSmall-capSEC EDGAR FY 2025-12-31

On the WireNo stories on MYGN yet. Follow the company and the next one lands in Following.

What happened

Daily closes · dots are Wire stories

What’s next

Expected around late October, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 3, 2025 and Nov 7, 2024, after the close.

Last report

Jul 30, 2026−46.74%

after the close

Last 4, next close

median 9.71% either way

up 1 of 4

Every report since 2023 →Earnings calendar →

DateEventSourceNext close

Jul 30Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗−46.74%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

What happened · big days

21 big days in a year, and what we hold on each

A big day is a close more than 6.69% from the one before, three times MYGN’s median day (2.23%). On 1 of the 21, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.

every other trading daya big day, numbered in the list below±6.69%Hover a bar for its day. Click a big day to open it.

Shaded: since our stories began, Jun 10. Tap a bar for its day.

#DayMYGNWhat we hold that dayGroup (median of 4) · each

1 Nov 4, 2025−21.03%
Resultsgroup −1.9%, did not move with it
1Nov 4, 2025−21.03%
ResultsFirst close after the Nov 3 results filing
−1.9% did not move with itNEOG −4.0 · CLDX −3.6 · IDXX −0.1 · LNTH +1.6
2 Nov 20, 2025+7.14%
Before our storiesgroup −0.3%, did not move with it
2Nov 20, 2025+7.14%
Before our stories
−0.3% did not move with itLNTH +1.5 · CLDX +0.6 · IDXX −1.1 · NEOG −2.9
3 Nov 21, 2025+6.96%
Before our storiesgroup +4.7%, moved with MYGN
3Nov 21, 2025+6.96%
Before our stories
+4.7% moved with MYGNNEOG +5.7 · IDXX +5.3 · LNTH +4.2 · CLDX +3.4
4 Dec 1, 2025−7.47%
Before our storiesgroup −2.1%, did not move with it
4Dec 1, 2025−7.47%
Before our stories
−2.1% did not move with itCLDX −4.1 · IDXX −3.2 · NEOG −1.0 · LNTH +0.4
5 Feb 25, 2026+7.90%
Before our storiesgroup +2.1%, did not move with it
5Feb 25, 2026+7.90%
Before our stories
+2.1% did not move with itCLDX +24.1 · LNTH +2.9 · IDXX +1.3 · NEOG +0.7
6 Mar 2, 2026+8.68%
Before our storiesgroup −0.5%, did not move with it
6Mar 2, 2026+8.68%
Before our stories
−0.5% did not move with itLNTH +1.9 · CLDX −0.3 · NEOG −0.7 · IDXX −3.0
7 Mar 27, 2026−7.36%
Before our storiesgroup −3.6%, did not move with it
7Mar 27, 2026−7.36%
Before our stories
−3.6% did not move with itNEOG −4.9 · CLDX −4.6 · IDXX −2.6 · LNTH −2.5
8 Apr 9, 2026−6.92%
Before our storiesgroup +0.3%, did not move with it
8Apr 9, 2026−6.92%
Before our stories
+0.3% did not move with itNEOG −3.0 · IDXX −1.2 · LNTH +1.8 · CLDX +3.7
9 Apr 14, 2026+6.97%
Before our storiesgroup +2.0%, did not move with it
9Apr 14, 2026+6.97%
Before our stories
+2.0% did not move with itNEOG +5.1 · CLDX +2.3 · IDXX +1.8 · LNTH +1.3
10 May 6, 2026−18.29%
Resultsgroup +1.0%, did not move with it
10May 6, 2026−18.29%
ResultsFirst close after the May 5 results filing
+1.0% did not move with itNEOG −1.0 · LNTH +0.4 · CLDX +1.6 · IDXX +2.9
11 May 13, 2026−8.35%
Before our storiesgroup +0.6%, did not move with it
11May 13, 2026−8.35%
Before our stories
+0.6% did not move with itIDXX −1.0 · LNTH +0.2 · NEOG +0.9 · CLDX +1.6
12 May 20, 2026+7.32%
Before our storiesgroup +3.0%, did not move with it
12May 20, 2026+7.32%
Before our stories
+3.0% did not move with itNEOG +5.8 · LNTH +3.4 · CLDX +2.5 · IDXX +1.3
13 May 28, 2026+7.38%
Before our storiesgroup +0.8%, did not move with it
13May 28, 2026+7.38%
Before our stories
+0.8% did not move with itIDXX +3.1 · NEOG +1.1 · LNTH +0.5 · CLDX +0.2
14 Jun 1, 2026+7.81%
Before our storiesgroup −1.4%, did not move with it
14Jun 1, 2026+7.81%
Before our stories
−1.4% did not move with itIDXX +0.6 · NEOG −0.6 · LNTH −2.2 · CLDX −4.1
15 Jun 24, 2026+12.74%
Nothing on MYGNgroup +1.9%, did not move with it
15Jun 24, 2026+12.74%
Nothing on MYGNNo MYGN story, brief or results filing in our record that day
+1.9% did not move with itNEOG +4.0 · CLDX +2.4 · IDXX +1.4 · LNTH −1.1
16 Jun 26, 2026+8.29%
Nothing on MYGNgroup +0.7%, did not move with it
16Jun 26, 2026+8.29%
Nothing on MYGNNo MYGN story, brief or results filing in our record that day
+0.7% did not move with itCLDX +3.4 · NEOG +0.7 · LNTH +0.7 · IDXX −0.6
17 Jul 31, 2026−46.74%
Resultsgroup −0.5%, did not move with it
17Jul 31, 2026−46.74%
ResultsFirst close after the Jul 30 results filing
−0.5% did not move with itLNTH −1.4 · CLDX −1.1 · IDXX +0.1 · NEOG +4.4
18 Aug 19, 2026+11.15%
Nothing on MYGNgroup +0.9%, did not move with it
18Aug 19, 2026+11.15%
Nothing on MYGNNo MYGN story, brief or results filing in our record that day
+0.9% did not move with itNEOG +5.0 · IDXX +1.6 · LNTH +0.2 · CLDX −0.2
19 Sep 14, 2026+10.82%
Nothing on MYGNgroup +1.2%, did not move with it
19Sep 14, 2026+10.82%
Nothing on MYGNNo MYGN story, brief or results filing in our record that day
+1.2% did not move with itCLDX +6.2 · NEOG +1.4 · IDXX +1.0 · LNTH +0.1
20 Sep 17, 2026+7.25%
Nothing on MYGNgroup +0.5%, did not move with it
20Sep 17, 2026+7.25%
Nothing on MYGNNo MYGN story, brief or results filing in our record that day
+0.5% did not move with itNEOG +2.2 · CLDX +0.7 · LNTH +0.3 · IDXX −1.4
21 Oct 2, 2026+11.82%
Nothing on MYGNgroup −0.3%, did not move with it
21Oct 2, 2026+11.82%
Nothing on MYGNNo MYGN story, brief or results filing in our record that day
−0.3% did not move with itLNTH +0.3 · IDXX +0.1 · NEOG −0.7 · CLDX −1.6

A story on the same day is not a cause, and a group move is not proof either. Group: the median of IDXX, LNTH, NEOG and CLDX that day, the largest companies in MYGN’s SEC industry; “moved with MYGN” means the same direction and at least half the size.

What’s next · results

Before the next report: what the first day after the last four did

Six trading days after each results filing (SEC 8-K, Item 2.02). Day 1 is the first close after each filing: the next day’s for a filing after the close, the same day’s otherwise. Each time, day 6 ended on the same side as day 1.

Reported Jan 12, 2026

day 1−0.15%day 6−13.68%

Reported Feb 23, 2026

day 1+1.14%day 6+20.78%

Reported May 5, 2026

day 1−18.29%day 6−25.84%

Reported Jul 30, 2026

day 1−46.74%day 6−39.29%

Next report: expected late OctoberEstimated from the dates of its last four results filings. Not announced. Since the Jul 30 report: −20.30%. Four reports is a small sample.

Every report since 2023 →

Each line is MYGN’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.

The numbers · FY2025, filed

SEC EDGAR

Market cap$409M

Revenue$824.5M−1.60%

Net income$-366.0M

EPS, diluted$-3.95−180.10%

Gross margin69.9%

Operating margin-47.0%

Return on equity-99.5%

Debt / equity0.49

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$409.4M

Enterprise Value$437.4M

Income$-366.0M

Sales$824.5M

Book/sh$3.85

Cash/sh$1.58

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio2.26

Current Ratio2.49

Debt/Eq0.49

EPS (ttm)$-3.95

EPS this Y-180.1%

EPS past 3/5Y—

Sales past 3/5Y6.7%

EPS Y/Y TTM-180.1%

Sales Y/Y TTM-1.6%

Shs Outstand95.65M

ROA-51.8%

ROE-99.5%

ROIC-90.5%

Gross Margin69.9%

Oper. Margin-47.0%

Profit Margin-44.4%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$690.6M

FY21

$678.4M

FY22

$753.2M

FY23

$837.6M

FY24

$824.5M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$690.6M	$678.4M	$753.2M	$837.6M	$824.5M
Gross Profit	—	$476.4M	$517.0M	$585.4M	$576.6M
Operating Income	$-190.5M	$-140.6M	$-257.4M	$-123.5M	$-387.2M
Net Income	$-27.0M	$-112.0M	$-263.0M	$-127.0M	$-366.0M
Diluted EPS	$-0.35	$-1.39	$-3.18	$-1.41	$-3.95
Operating Cash Flow	$18.6M	$-106.3M	$-110.9M	$-8.7M	$1.8M
Free Cash Flow	—	—	—	—	—

Same industry

MYGN against four same-industry peers, a year at 100

MYGN is down 42.9% in a year. Neogen is up 98.0%, Lantheus Holdings 86.7%, Celldex Therapeutics 15.8% and Idexx Laboratories is down 16.3%. All four did more. Weekly closes, Oct 10, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.

Share this chart

MYGN −42.9%. Neogen +98.0%, Lantheus Holdings +86.7%, Celldex Therapeutics +15.8%, Idexx Laboratories −16.3%. Weekly closes, Oct 10, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in MYGN’s SEC industry (In Vitro & In Vivo Diagnostic Substances) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

Same industry

In the screener →

IDXX$40.6B LNTH$6.5B NEOG$2.6B CLDX$2.4B NTLA$1.7B QDEL$862M TKNO$470M NNNN$214M

Build basket with MYGN Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.